Fatal Hypogammaglobulinemia 3 Years after Rituximab in a Patient with Immune Thrombocytopenia: An Underlying Genetic Predisposition?
We report the case of a young woman who developed, 3 years after stopping Rituximab (RTX) prescribed for immune thrombocytopenia (ITP), a severe immunodeficiency leading to fatal pulmonary Epstein–Barr virus-positive diffuse large B-cell lymphoma. Genetic analysis led us to identify four missense mu...
Main Authors: | Jean-François Viallard, Marie Parrens, Frédéric Rieux-Laucat |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Case Reports in Immunology |
Online Access: | http://dx.doi.org/10.1155/2019/2543038 |
Similar Items
-
Late-onset hypogammaglobulinemia after rituximab therapy
by: O V Moskalets
Published: (2019-12-01) -
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
by: Joanna Tieu, et al.
Published: (2021-05-01) -
Hypogammaglobulinemia Observed One Year after Rituximab Treatment for Idiopathic Thrombocytopenic Purpura
by: Bilal Ahmad Shoukat, et al.
Published: (2018-01-01) -
Antigenic Mimicry in Paraneoplastic Immune Thrombocytopenia
by: Guillaume Vial, et al.
Published: (2019-03-01) -
Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
by: Amer M. Khojah, et al.
Published: (2019-08-01)